

# Eva Bandres

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6939872/eva-bandres-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

54  
papers

3,661  
citations

29  
h-index

55  
g-index

55  
ext. papers

3,965  
ext. citations

5.2  
avg, IF

4.4  
L-index

#	Paper	IF	Citations
54	Epigenetic regulation of microRNA expression in colorectal cancer. <i>International Journal of Cancer</i> , <b>2009</b> , 125, 2737-43	7.5	372
53	microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 2281-90	12.9	299
52	miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. <i>Carcinogenesis</i> , <b>2009</b> , 30, 1903-9	4.6	282
51	Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. <i>Cancer Research</i> , <b>2009</b> , 69, 4443-53	10.1	263
50	MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. <i>Stem Cells</i> , <b>2011</b> , 29, 1661-71	5.8	222
49	Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. <i>Molecular Cancer Research</i> , <b>2008</b> , 6, 1830-40	6.6	168
48	Overlapping expression of microRNAs in human embryonic colon and colorectal cancer. <i>Cell Research</i> , <b>2008</b> , 18, 823-33	24.7	159
47	Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. <i>PLoS ONE</i> , <b>2011</b> , 6, e26740	3.7	157
46	Biological profile of new apoptotic agents based on 2,4-pyrido[2,3-d]pyrimidine derivatives. <i>Bioorganic and Medicinal Chemistry</i> , <b>2007</b> , 15, 1659-69	3.4	132
45	miRNA cargo within exosome-like vesicle transfer influences metastatic bone colonization. <i>Molecular Oncology</i> , <b>2014</b> , 8, 689-703	7.9	131
44	miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. <i>Molecular Cancer Therapeutics</i> , <b>2010</b> , 9, 2265-75	6.1	131
43	Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1316-22	2.2	120
42	SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. <i>Blood</i> , <b>2010</b> , 115, 615-25	2.2	114
41	Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. <i>Pharmacogenomics Journal</i> , <b>2011</b> , 11, 429-36	3.5	89
40	Choline kinase as a link connecting phospholipid metabolism and cell cycle regulation: implications in cancer therapy. <i>International Journal of Biochemistry and Cell Biology</i> , <b>2008</b> , 40, 1753-63	5.6	69
39	TWIST1 overexpression is associated with nodal invasion and male sex in primary colorectal cancer. <i>Annals of Surgical Oncology</i> , <b>2009</b> , 16, 78-87	3.1	59
38	Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 1774-80	7.5	56

37	MicroRNAs as cancer players: potential clinical and biological effects. <i>DNA and Cell Biology</i> , <b>2007</b> , 26, 273-82	3.6	56
36	Vascular endothelial growth factor (VEGF) and melanoma. N-acetylcysteine downregulates VEGF production in vitro. <i>Cytokine</i> , <b>2000</b> , 12, 374-8	4	52
35	Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer. <i>Molecular Cancer Therapeutics</i> , <b>2009</b> , 8, 194-202	6.1	51
34	Prognostic implications of miR-16 expression levels in resected non-small-cell lung cancer. <i>Journal of Surgical Oncology</i> , <b>2011</b> , 103, 411-5	2.8	48
33	Alpha-MSH regulates interleukin-10 expression by human keratinocytes. <i>Archives of Dermatological Research</i> , <b>1998</b> , 290, 425-8	3.3	48
32	Cdc42 is highly expressed in colorectal adenocarcinoma and downregulates ID4 through an epigenetic mechanism. <i>International Journal of Oncology</i> , <b>2008</b> , 33, 185-93	1	46
31	A gene signature of 8 genes could identify the risk of recurrence and progression in DukesSB colon cancer patients. <i>Oncology Reports</i> , <b>2007</b> , 17, 1089-94	3.5	44
30	miR-326 associates with biochemical markers of bone turnover in lung cancer bone metastasis. <i>Bone</i> , <b>2013</b> , 52, 532-9	4.7	40
29	Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. <i>British Journal of Cancer</i> , <b>2010</b> , 102, 987-94	8.7	39
28	Epidermal growth factor receptor (EGFR) polymorphisms and survival in head and neck cancer patients. <i>Oral Oncology</i> , <b>2007</b> , 43, 713-9	4.4	32
27	Characterization of cisplatin cytotoxicity delivered from PLGA-systems. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2008</b> , 68, 503-12	5.7	31
26	Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients. <i>British Journal of Cancer</i> , <b>2012</b> , 107, 287-90	8.7	30
25	Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array. <i>World Journal of Gastroenterology</i> , <b>2012</b> , 18, 637-45	5.6	28
24	MiRNAs and LincRNAs: Could they be considered as biomarkers in colorectal cancer?. <i>International Journal of Molecular Sciences</i> , <b>2012</b> , 13, 840-65	6.3	27
23	Differential expression of Rac1 identifies its target genes and its contribution to progression of colorectal cancer. <i>International Journal of Biochemistry and Cell Biology</i> , <b>2007</b> , 39, 2289-302	5.6	24
22	Proteomic analysis in cancer research: potential application in clinical use. <i>Clinical and Translational Oncology</i> , <b>2006</b> , 8, 250-61	3.6	23
21	Combining chemotherapy and targeted therapies in metastatic colorectal cancer. <i>World Journal of Gastroenterology</i> , <b>2007</b> , 13, 5867-76	5.6	23
20	Pharmacogenomics in colorectal cancer: the first step for individualized-therapy. <i>World Journal of Gastroenterology</i> , <b>2007</b> , 13, 5888-901	5.6	23

19	New symmetrical quinazoline derivatives selectively induce apoptosis in human cancer cells. <i>Cancer Biology and Therapy</i> , <b>2006</b> , 5, 850-9	4.6	21
18	The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients. <i>Cellular and Molecular Life Sciences</i> , <b>2015</b> , 72, 4049-62	10.3	18
17	Moving forward in colorectal cancer research, what proteomics has to tell. <i>World Journal of Gastroenterology</i> , <b>2007</b> , 13, 5813-21	5.6	16
16	Development of a DNA Microelectrochemical Biosensor for CEACAM5 Detection. <i>IEEE Sensors Journal</i> , <b>2010</b> , 10, 1368-1374	4	14
15	Gene expression profile of ewing sarcoma cell lines differing in their EWS-FLI1 fusion type. <i>Journal of Pediatric Hematology/Oncology</i> , <b>2005</b> , 27, 537-42	1.2	14
14	Hematological response of topotecan in tumor-bearing rats: modeling of the time course of different cellular populations. <i>Pharmaceutical Research</i> , <b>2004</b> , 21, 567-73	4.5	12
13	Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. <i>Journal of Neuro-Oncology</i> , <b>2005</b> , 73, 189-98	4.8	10
12	Association of steroid and xenobiotic receptor (SXR) and multidrug resistance 1 (MDR1) gene expression with survival among patients with invasive bladder carcinoma. <i>BJU International</i> , <b>2011</b> , 107, 1833-8	5.6	9
11	Functional specific-T-cell expansion after first cytomegalovirus reactivation predicts viremia control in allogeneic hematopoietic stem cell transplant recipients. <i>Transplant Infectious Disease</i> , <b>2017</b> , 19, e12778	7.7	8
10	Dysregulation of apoptosis is a major mechanism in the lymph node involvement in colorectal carcinoma. <i>Oncology Reports</i> , <b>2004</b> , 12, 287-92	3.5	8
9	Streptamer technology allows accurate and specific detection of CMV-specific HLA-A*02 CD8 T cells by flow cytometry. <i>Cytometry Part B - Clinical Cytometry</i> , <b>2017</b> , 92, 153-160	3.4	7
8	Clinical relevance of the transcriptional signature regulated by CDC42 in colorectal cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 26755-26770	3.3	7
7	Epigenetic Regulation of microRNAs in Cancer: Shortening the Distance from Bench to Bedside. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	7
6	Impact of T cell selection methods in the success of clinical adoptive immunotherapy. <i>Cellular and Molecular Life Sciences</i> , <b>2014</b> , 71, 1211-24	10.3	5
5	The abrogation of TCR-independent interactions with human serum ensures a selective capture of therapeutic virus-specific CD8+ T-cells by multimer technology in Adoptive Immunotherapy. <i>Journal of Immunological Methods</i> , <b>2013</b> , 396, 168-72	2.5	5
4	Assessment of Minimal Residual Disease by Next Generation Sequencing in Peripheral Blood as a Complementary Tool for Personalized Transplant Monitoring in Myeloid Neoplasms. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	4
3	Semi-mechanistic description of the in-vitro antiproliferative effect of different antitumour agents. <i>Journal of Pharmacy and Pharmacology</i> , <b>2008</b> , 60, 77-82	4.8	3
2	A semi-physiological-based pharmacokinetic/pharmacodynamic model to describe the effects of topotecan on b-lymphocyte lineage cells. <i>Pharmaceutical Research</i> , <b>2010</b> , 27, 431-41	4.5	3

- 1 Identification of two HLA-C alleles with new amino acid residues in the EB domain, HLA-C\*03:581 and -C\*05:267.. *Hla*, **2021**, 1.9 2